Conclusion: In patients with EGFR-mutated NSCLC, first and third generation EGFR tyrosine kinase inhibitors, as well as combination therapies with antiangiogenesis, were associated with increased risks of cardiovascular adverse events. Risks were significantly higher with third generation compared with first generation inhibitors.
PubMed 40897431 ↗Tyrosine
Also known as L-Tyrosine, NALT, N-Acetyl L-Tyrosine
The short answer. More people than not who report on Tyrosine say it helped (55% of 632). It is most often used for focus: 85% of 294 reports say that improved. It is well studied — 2,190 meta-analyses on PubMed. The most common complaint is anxiety.
From 1,662 mentions in total — the rest didn't say how it went and aren't counted.
What Tyrosine does, according to users
Of the people who reported each effect, the share who said it got better.
4 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 2,190 meta-analyses on PubMed ↗ · 1,766 randomized trials ↗
Conclusion: For individuals with advanced EGFR-mutated NSCLC who progressed on EGFR-TKIs, ICI-antiangio-chemo was identified as the optimal treatment option. The toxicity of this treatment was acceptable but needs careful attention. ICI-chemo showed appreciably greater efficacy than the standard-of-care chemotherapy. These findings clarified the roles of ICI-based treatment strategies in this difficult-to-treat refractory population, potentially complementing recent guidelines.
PubMed 39159630 ↗Conclusion: Our NMA analysis adds to existing findings and supplements data gaps from other published NMAs. Findings from eight published NMAs consistently supported lorlatinib as a clinically effective 1L treatment for ALK + advanced NSCLC patients compared to other TKIs.
PubMed 39368244 ↗Conclusion: Further, OS benefits of ICI doublets were not inferior to those of ICI + tyrosine kinase inhibitor combinations. Recommendation of combination therapies with ICIs and/or tyrosine kinase inhibitors based on survival benefits and patient pretreatment risk classification will help advance personalized medicine for mRCC.
PubMed 38289361 ↗2,101 human trials on ClinicalTrials.gov test Tyrosine — 939 completed, 280 recruiting now. See all on ClinicalTrials.gov ↗
- Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung Adenocarcinoma · Lung Cancer Stage III, EGFR Activating Mutation · 2026
- Pre-workout Supplement, Arrhythmias and Exercise Stress Test · Supplementation During Endurance Performance · 2026
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) · Carcinoma, Renal Cell · 2026
Reports to the FDA
Adverse-event reports about supplements containing it, submitted to the US FDA by consumers and doctors.
15 reports name a product containing Tyrosine (2009–2021); 9 involved hospitalization or worse. Most often reported:
- Hepatic enzyme increased · 3
- Autoimmune hepatitis · 2
- Hypoaesthesia · 2
- Vision blurred · 2
- Headache · 2
- Malaise · 2
A report doesn't prove the supplement caused the problem — many products contain several ingredients, and these counts can't tell you how often it happens. Source: FDA CAERS ↗ · raw reports (openFDA) ↗.
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
1 recall of products named for Tyrosine. Most recent:
- 2017-01-04 · Class II: Pursuant to a consent decree that prohibits the company and its owners for marketing dietary supplements until they, among other things, recall and destroy… record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
- Helps to decrease cognitive fatigue due to physically stressful situations (e.g. extended wakefulness, exposure to cold, excessive noise).
Required cautions: Ask a health care practitioner before use if you are pregnant or breastfeeding.
No health claim for Tyrosine is authorised in the EU.
6 proposed claims were rejected, usually because EFSA found the evidence insufficient (example ↗).
Dosage people report
As stated by users — not a recommendation. Follow the label or your doctor.
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I stack taurine with tyrosine and creatine and that has helped my mood noticeably and also helps me feel stronger and more energetic.”
“L-Tyrosine gives me nothing but the shakes that feel similar to a blood glucose crash.”
“I tried so many things for depression like saffron rhodiola tyrosine omega 3 methylfolate B12 taurine theanine NAC inositol b complex magnesium nothing helps it.”
“despite taking it multiple times daily for about 4 years, I still seem to very consistently get strong positive effects from L-tyrosine...Light euphoria, motivation, energy, etc.”
Tyrosine compared
Other options for focus
Sources
- User reports: 1,662 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA recalls ↗
- Health Canada ↗
- EU health-claims register ↗
- US Food and Drug Administration: CAERS adverse-event reports ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate